Takara Holdings Inc.
Investigation Results Regarding Uncertainties in Accounting Treatments of Consolidated Subsidiary Takara Bio USA, Inc.
An investigation, including external specialists, was conducted into uncertainties regarding accounting treatments at Takara Bio USA. The investigation concluded that although some uncertainties remained, no misstatements of quantitative significance were identified and there is no need to restate prior consolidated financial statements. The interim review concluded with an unqualified opinion.
Key Figures
- Received interim review report with an unqualified opinion
- Only misstatements not quantitatively significant were identified
- No need to correct prior consolidated financial statements
AI要約
Overview and Background of the Investigation
Based on the timely disclosure published on August 12, 2026, the Company conducted an investigation into uncertainties in the accounting treatments of consolidated subsidiary Takara Bio USA. An investigative framework including external specialists was established, and extensive procedures including digital forensic investigations were performed. The investigation was carried out mainly from August 6, 2026 to October 14, 2026.
Investigation Conclusion and Future Measures
The investigation found that while uncertainties existed in Takara Bio USA's prior accounting treatments, no misstatements of quantitative significance were confirmed, and it was concluded that there is no need to correct prior consolidated financial statements. In consultation with the statutory auditor, the interim review report was received with an unqualified opinion. Going forward, the Company will work to strengthen the financial reporting process and improve coordination.
Takara Holdings Inc.
Company overview · Stock price · Financial data · All IR
